Secondary Prevention in Coronary Heart Disease.

Trial Profile

Secondary Prevention in Coronary Heart Disease.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Influenza virus vaccine (Primary) ; ACE inhibitors; Angiotensin type 1 receptor antagonists; Antihyperglycaemics; Atorvastatin; Beta-adrenergic receptor antagonists; Cardiovascular therapies; Diuretics; Ezetimibe; Glimepiride; HMG-CoA reductase inhibitors; Insulin; Metformin; Moxonidine; Nicotine replacement therapy; Simvastatin; Varenicline
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms SPREK!
  • Most Recent Events

    • 08 Aug 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2024 as reported by ClinicalTrials.gov record.
    • 08 Aug 2017 Planned Primary completion date changed fr5om 1 Dec 2016 to 1 Dec 2024
    • 08 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top